{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:07:55Z","timestamp":1781993275201,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Outcomes of pediatric and young adult patients diagnosed with acute lymphoblastic leukemia (ALL) have improved significantly in the past few decades. Treatment advances have provided 5-year survival rates ranging from 78 to 91% depending on the age at diagnosis. However, approximately 2\u20133% of patients will present with refractory disease that is unresponsive to chemotherapy, and 10\u201315% of patients will relapse. Outcomes post-relapse show significantly reduced 5-year survival rates that continue to decrease with each subsequent relapse. Despite our increased understanding of risk factors and disease predictors, treatment strategies for patients with relapsed or refractory (r\/r) disease, including variations of chemotherapy and stem cell transplant, remain ineffective for many patients. To improve outcomes of patients with r\/r disease, immunotherapies targeting specific B cell antigens are being developed. Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy recently approved by the US Food and Drug Administration for patients with refractory leukemia or those with second or later relapse. In this treatment strategy, a patient\u2019s own T cells are transduced to express an anti-CD19 CAR that, when reintroduced into the patient, directs specific binding and killing of CD19+ B cells. In a phase 2, single-arm, multicenter, global study, tisagenlecleucel resulted in a remission rate of 81% in pediatric and adolescent patients with r\/r B cell ALL. This review article summarizes four typical cases of pediatric and adolescent r\/r B-cell ALL, focusing on the patient\u2019s journey from initial diagnosis to treatment with CAR T cell therapy.<\/jats:p>","DOI":"10.1038\/s41408-018-0164-6","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T17:06:01Z","timestamp":1548176761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL"],"prefix":"10.1038","volume":"9","author":[{"given":"George","family":"Hucks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"164_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/pbc.24420","volume":"60","author":"SP Hunger","year":"2013","unstructured":"Hunger, S. P. et al. Children\u2019s Oncology Group\u2019s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr. Blood Cancer 60, 957\u2013963 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"164_CR2","unstructured":"Howlader, N. et al. SEER Cancer Statistics Review, 1975-2014 (National Cancer Institute, Bethesda, MD, 2017). Available at: http:\/\/seer.cancer.gov\/csr\/1975_2014\/. Accessed 16 Aug 2017."},{"key":"164_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 64, 83\u2013103 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"164_CR4","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.28748","volume":"120","author":"MA Smith","year":"2014","unstructured":"Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H. & Seibel, N. L. Declining childhood and adolescent cancer mortality. Cancer 120, 2497\u20132506 (2014).","journal-title":"Cancer"},{"key":"164_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541\u20131552 (2015).","journal-title":"N. Engl. J. Med."},{"key":"164_CR6","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","volume":"366","author":"M Schrappe","year":"2012","unstructured":"Schrappe, M. et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 366, 1371\u20131381 (2012).","journal-title":"N. Engl. J. Med."},{"key":"164_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","volume":"29","author":"CH Pui","year":"2011","unstructured":"Pui, C. H., Carroll, W. L., Meshinchi, S. & Arceci, R. J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551\u2013565 (2011).","journal-title":"J. Clin. Oncol."},{"key":"164_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","volume":"28","author":"RH Ko","year":"2010","unstructured":"Ko, R. H. et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 28, 648\u2013654 (2010).","journal-title":"J. Clin. Oncol."},{"key":"164_CR9","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen, K. et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia 22, 2142\u20132150 (2008).","journal-title":"Leukemia"},{"key":"164_CR10","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","volume":"120","author":"F Locatelli","year":"2012","unstructured":"Locatelli, F., Schrappe, M., Bernardo, M. E. & Rutella, S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120, 2807\u20132816 (2012).","journal-title":"Blood"},{"key":"164_CR11","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","volume":"35","author":"B Reismuller","year":"2013","unstructured":"Reismuller, B. et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J. Pediatr. Hematol. Oncol. 35, e200\u2013e204 (2013).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"164_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1365-2141.2003.04584.x","volume":"123","author":"JM Chessells","year":"2003","unstructured":"Chessells, J. M. et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br. J. Haematol. 123, 396\u2013405 (2003).","journal-title":"Br. J. Haematol."},{"key":"164_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","volume":"17","author":"CH Pui","year":"2017","unstructured":"Pui, C. H., Roberts, K. G., Yang, J. J. & Mullighan, C. G. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 17, 464\u2013470 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"164_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli, F. et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T cell and B-cell depletion. Blood 130, 677\u2013685 (2017).","journal-title":"Blood"},{"key":"164_CR15","doi-asserted-by":"crossref","unstructured":"Barredo, J. C. et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J. Clin. Oncol. 24, 3142\u20133149 (2006).","DOI":"10.1200\/JCO.2005.03.3373"},{"key":"164_CR16","doi-asserted-by":"crossref","unstructured":"Uderzo, C. et al. Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. Associazione Italiana Ematologia ed Oncologia Pediatrica. J. Clin. Oncol. 8, 672\u2013677 (1990).","DOI":"10.1200\/JCO.1990.8.4.672"},{"key":"164_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MPH.0b013e3182352da9","volume":"34","author":"UM Saarinen-Pihkala","year":"2012","unstructured":"Saarinen-Pihkala, U. M. et al. RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children. J. Pediatr. Hematol. Oncol. 34, 263\u2013270 (2012).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"164_CR18","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz, E. A. et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group pilot study. J. Clin. Oncol. 26, 3756\u20133762 (2008).","journal-title":"J. Clin. Oncol."},{"key":"164_CR19","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker, C. et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376, 2009\u20132017 (2010).","journal-title":"Lancet"},{"key":"164_CR20","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen, G. et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J. Clin. Oncol. 28, 2339\u20132347 (2010).","journal-title":"J. Clin. Oncol."},{"key":"164_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/sj.leu.2405037","volume":"22","author":"M Eapen","year":"2008","unstructured":"Eapen, M. et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children\u2019s Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 22, 281\u2013286 (2008).","journal-title":"Leukemia"},{"key":"164_CR22","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1182\/blood-2005-12-4942","volume":"107","author":"M Eapen","year":"2006","unstructured":"Eapen, M. et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children\u2019s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107, 4961\u20134967 (2006).","journal-title":"Blood"},{"key":"164_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/blood-2012-07-441030","volume":"120","author":"MS Topp","year":"2012","unstructured":"Topp, M. S. et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL) [abstract 670]. Blood 120, 670 (2012).","journal-title":"Blood"},{"key":"164_CR24","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg, A. et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381\u20134389 (2016).","journal-title":"J. Clin. Oncol."},{"key":"164_CR25","doi-asserted-by":"crossref","unstructured":"Maude, S. L. et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL. J. Clin. Oncol. 34(suppl 15), Abstract 3011 (2016).","DOI":"10.1200\/JCO.2016.34.15_suppl.3011"},{"key":"164_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"164_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"164_CR28","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2016-10-748772","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322\u20133331 (2017).","journal-title":"Blood"},{"key":"164_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"164_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell, J. A. et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N. Engl. J. Med. 358, 877\u2013887 (2008).","journal-title":"N. Engl. J. Med."},{"key":"164_CR31","doi-asserted-by":"crossref","unstructured":"Crotta, A., Keir, C., Thomas, S. K. & Armstrong, L. Disease characteristics and overall survival in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia after stem cell transplant. Biol. Blood Marrow Transplant. 23(S18\u2013S391), Abstract 42 (2017).","DOI":"10.1016\/j.bbmt.2016.12.014"},{"key":"164_CR32","doi-asserted-by":"crossref","unstructured":"Hunger, S. P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 1663\u20131669 (2012).","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"164_CR33","doi-asserted-by":"crossref","unstructured":"Krull, K. R. et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude Lifetime Cohort Study. J. Clin. Oncol. 31, 4407\u20134415 (2013).","DOI":"10.1200\/JCO.2012.48.2315"},{"key":"164_CR34","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","volume":"34","author":"EC Larsen","year":"2016","unstructured":"Larsen, E. C. et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232. J. Clin. Oncol. 34, 2380\u20132388 (2016).","journal-title":"J. Clin. Oncol."},{"key":"164_CR35","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz, E. A. et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study [corrected]. J. Clin. Oncol. 26, 3971\u20133978 (2008).","journal-title":"J. Clin. Oncol."},{"key":"164_CR36","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","volume":"127","author":"C Schwab","year":"2016","unstructured":"Schwab, C. et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 127, 2214\u20132218 (2016).","journal-title":"Blood"},{"key":"164_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005\u20131015 (2014).","journal-title":"N. Engl. J. Med."},{"key":"164_CR38","doi-asserted-by":"crossref","unstructured":"Tran, T. H. & Loh, M. L. Ph-like acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2016, 561\u2013566 (2016).","DOI":"10.1182\/asheducation-2016.1.561"},{"key":"164_CR39","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","volume":"115","author":"P Stow","year":"2010","unstructured":"Stow, P. et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 115, 4657\u20134663 (2010).","journal-title":"Blood"},{"key":"164_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","volume":"100","author":"E Coustan-Smith","year":"2002","unstructured":"Coustan-Smith, E. et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100, 52\u201358 (2002).","journal-title":"Blood"},{"issue":"1 Suppl","key":"164_CR41","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1016\/j.bbmt.2010.10.005","volume":"17","author":"MA Pulsipher","year":"2011","unstructured":"Pulsipher, M. A., Peters, C. & Pui, C. H. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol. Blood Marrow Transplant. 17(1 Suppl), S137\u2013S148 (2011).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"164_CR42","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"164_CR43","doi-asserted-by":"publisher","unstructured":"Bhojwani, D. et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia https:\/\/doi.org\/10.1038\/s41375-018-0265-z (2018).","DOI":"10.1038\/s41375-018-0265-z"},{"key":"164_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","volume":"355","author":"H Hasle","year":"2000","unstructured":"Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. Lancet 355, 165\u2013169 (2000).","journal-title":"Lancet"},{"key":"164_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1365-2141.2006.06337.x","volume":"135","author":"JA Whitlock","year":"2006","unstructured":"Whitlock, J. A. Down syndrome and acute lymphoblastic leukaemia. Br. J. Haematol. 135, 595\u2013602 (2006).","journal-title":"Br. J. Haematol."},{"key":"164_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.leu.2400989","volume":"12","author":"M Dordelmann","year":"1998","unstructured":"Dordelmann, M. et al. Down\u2019s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 12, 645\u2013651 (1998).","journal-title":"Leukemia"},{"key":"164_CR47","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","volume":"19","author":"A Bosi","year":"2001","unstructured":"Bosi, A. et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J. Clin. Oncol. 19, 3675\u20133684 (2001).","journal-title":"J. Clin. Oncol."},{"key":"164_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","volume":"34","author":"M Eapen","year":"2004","unstructured":"Eapen, M. et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 34, 721\u2013727 (2004).","journal-title":"Bone Marrow Transplant."},{"key":"164_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18620\/1866-8836-2016-5-2-12-20","volume":"5","author":"S Bondarenko","year":"2016","unstructured":"Bondarenko, S. et al. Allogeneic stem cell transplantation in children and adults with acute lymphoblastic leukemia. Cell. Ther. Transplant. 5, 12\u201320 (2016).","journal-title":"Cell. Ther. Transplant."},{"key":"164_CR50","doi-asserted-by":"publisher","unstructured":"Johnston, D. L. et al. Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Pediatr. Blood Cancer https:\/\/doi.org\/10.1002\/pbc.26612 (2017).","DOI":"10.1002\/pbc.26612"},{"key":"164_CR51","doi-asserted-by":"crossref","unstructured":"Rheingold, S. L. et al. Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/combined relapsed\/refractory ALL. Blood 126, Abstract 3769 (2015).","DOI":"10.1182\/blood.V126.23.3769.3769"},{"key":"164_CR52","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/pbc.24918","volume":"61","author":"JK Hitzler","year":"2014","unstructured":"Hitzler, J. K. et al. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr. Blood Cancer 61, 1126\u20131128 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"164_CR53","unstructured":"Laetsch, T. W. et al. CTL019 therapy appears safe and effective in pediatric patients with Down syndrome with relapsed\/refractory (r\/r) acute lymphoblastic leukemia. Blood 130, Abstract 1280 (2017)."},{"key":"164_CR54","doi-asserted-by":"crossref","unstructured":"Mahmoudjafari, Z. et al. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States. Biol. Blood Marrow Transplant. 25, 26\u201333 (2019).","DOI":"10.1016\/j.bbmt.2018.09.024"},{"key":"164_CR55","unstructured":"Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45\u201363 (2019)."},{"key":"164_CR56","doi-asserted-by":"crossref","unstructured":"Mueller, K. T. et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317\u20132325 (2017).","DOI":"10.1182\/blood-2017-06-786129"},{"key":"164_CR57","doi-asserted-by":"crossref","unstructured":"Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 24, 6175\u20136184 (2018).","DOI":"10.1158\/1078-0432.CCR-18-0758"},{"key":"164_CR58","doi-asserted-by":"crossref","unstructured":"Maude, S. L. et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relpased\/refractory acute lymphoblastic leukemia. Blood 128, Abstract 217 (2016).","DOI":"10.1182\/blood.V128.22.217.217"},{"key":"164_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. Emergence of CD19-neg disease is considered a cause of CD19 CAR-T treatment failure CD22 directed CAR therapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0164-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:09:26Z","timestamp":1671206966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0164-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0164-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.R. reports spouse employment by Optinose, Inc., research funding from Pfizer, Inc., and consultancy with Novartis Pharmaceuticals Corporation, outside the submitted work. The other author declares that he has no conflict of interest. Both authors acknowledge nonfinancial support from ArticulateScience LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"10"}}